{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Toxicity is calculated in terms of adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0","groups":[{"description":"Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"populationDescription":"The study was terminated early after the enrollment of two participants and the data were not collected.","reportingStatus":"POSTED","timeFrame":"30 days from the last dose of study drug","title":"Toxicity","type":"SECONDARY"}